三七总皂苷治疗慢性阻塞性肺疾病急性加重合并呼吸衰竭的临床研究

目的观察三七总皂苷治疗慢性阻塞性肺疾病急性加重合并呼吸衰竭患者临床疗效。方法 100例慢性阻塞性肺疾病急性加重合并呼吸衰竭患者随机分为常规药物组和三七皂苷组,观察两组治疗前后临床症状体征以及白细胞计数（WBC）、中性粒细胞（N）、血沉（ESR）、C反应蛋白（CRP）、动脉氧分压（PaO2）和动脉二氧化碳分压（PaCO2）的变化。结果治疗后临床疗效显著,三七皂苷组总有效率为96%,高于对照组的86%。;两组治疗后WBC、N、ESR、CRP水平明显下降,而三七皂苷组WBC由治疗前的（10.585±4.201）×109/L下降至（8.719±2.999）×109/L;N由治疗前的（0.769±0.103）下降至（0.693±0.126）;ESR由治疗前的（38.182±29.198）mm/h下降至（13.955±10.477）mm/h;CRP由治疗前的（37.542±20.318）mg/L下降至（7.250±5.127）mg/L,改善更为显著;治疗后PaO2和PaCO2均较治疗前改善,而三七皂苷组PaO2由治疗前的（74.625±32.552）mm Hg（1 mm Hg=0.133 kPa）升高至（85.839±23.476）mm Hg;PaCO2由治疗前的（68.537±15.844）mm Hg下降至（41.316±4.940）mm Hg,改善更为显著,差异有统计学意义（P〈0.05或P〈0.01）。结论三七总皂苷可改善慢性阻塞性肺疾病急性加重合并呼吸衰竭患者临床症状,WBC、N、ESR、CRP明显下降,PaO2上升和PaCO2下降。三七皂苷有良好的抑制炎性反应和抗感染治疗作用;亦能改善低氧,减轻二氧化碳潴留,从而改善患者气道通气功能。

Clinical research of Panax notoginseng saponins on patients of acute exacerbation of chronic obstructive pulmonary disease with respiratory failure

Objective To investigate clinical curative effect of Panax notoginseng saponins（PNS） on patients of acute exacerbation of chronic obstructive pulmonary disease（AECOPD） with respiratory failure. Methods 100 patients of AECOPD with respiratory failure were divided into control group（n=50） and PNS group（n=50）. The quantity of leukocyte in peripheral blood（WBC）,the quotient of the quantity of neutrophil to eukocyte in peripheral blood（N）,the erythrocyte sedimentation rate（ESR）,the serum levels of C-reaction protein（CRP）,the arterial partial pressure of oxygen（PaO2） and the arterial partial pressure of carbon dioxide（PaCO2） of patients in the two groups were detected. Results After treatment,curative effect were improved in the two groups,the total effective power of PNS group（96%） was obviously higher than that of the control group（86%）,and the effects were obviously more compared with the control group on WBC,N,ESR,CRP,PaO2 and PaCO2 （10.585±4.201）×109/L,（0.769±0.103）,（38.182±29.198） mm/h,（37.542±20.318） mg/L,（74.625±32.552） mm Hg（1 mm Hg = 0.133 kPa）,（68.537 ±15.844） mm Hg vs（8.719 ±2.999） ×109/L,（0.693 ±0.126）,（13.955 ±10.477） mm/h,（7.250 ±5.127） mg/L,（85.839 ±23.476） mm Hg,（41.316 ±4.940） mm Hg,respectively,P〈 0.05 or P 0.01]. Conclusion PNS can improve the WBC,N,ESR,CRP,PaO2 and PaCO2 levels in patients,and can enhance anti-inflammatory activities,increase PaO2,lighten PaCO2,improve pulmonary ventilation function,meanwhile it plays a prominent role in inhibiting airway inflammatory and obstruction process.